Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - cell+therapy

5 Results Sort By:

Gum-health promoting smart dental implant system

Dental implant that inhibits plaque accumulation and gingival tissue inflammation by photobiomodulation therapy delivered by embedded light-emitting diodes (LEDs) powered by electricity generated from the patient’s own oral motion. Problem: More than half of adults will lose one or more teeth in their lifetime. When a patient loses a tooth the...

Published: 2/9/2021

Inventor(s):

Keywords(s):

Category(s):

High performance CRISPR-Cas12a system for combinatorial genetic manipulation

CRISPR-Cas12a allowing for simultaneous editing of multiple genes in mammalian cells Problem: CRISPR-based gene editing technique has revolutionized the field of molecular biology. While CRISPR-Cas9-based methods are effectively used for single-gene knockout, multiplex gene editing remains a major challenge. Unlike Cas9, Cas12a can be used for multigene...

Published: 11/5/2020

Inventor(s):

Keywords(s):

Category(s):

Novel inhibitors of ferroptosis

Novel derivatives of oleic acid effectively inhibiting ferroptosis that could be used for treatment of Friedreich Ataxia, neurodegenerative diseases, and neuropsychiatric diseases. Problem: Ferroptosis is a non-apoptotic form of cell death characterized by the iron-dependent accumulation of toxic lipid-reactive oxygen species. Ferroptosis has been...

Published: 10/16/2020

Inventor(s):

Keywords(s):

Category(s):

Rapid and ultrasensitive profiling of EGFRvIII mutations in cancer and normal tissue

A method to rapidly detect the presence of EGFRvIII mutations in cancers and normal tissue using digital PCR. Problem: Glioblastoma multiforme (GBM) is a devastating brain cancer with poor prognosis. EGFRvIII is a mutation in the Extracellular Growth Factor Receptor that frequently occurs in GBM tumors. Targeting EGFRvIII mutations is an emerging...

Published: 10/5/2020

Inventor(s):

Keywords(s):

Category(s):

Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells

The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing...

Published: 1/29/2020

Inventor(s):

Keywords(s):

Category(s):